Literature DB >> 28360580

Acute Treatment of Migraine.

Vesile Öztürk1.   

Abstract

Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient's quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate-severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours. Migraine remains underdiagnosed and undertreated despite advances in the understanding of its pathophysiology. This article reviews management of migraine acute pharmacological treatment. Currently, for the acute treatment of migraine attacks, non-steroidal anti-inflammatory drugs (NSAIDs) and triptans (serotonin 5HT1B/1D receptor agonists) are recommended. Before intake of NSAID and triptans, metoclopramide or domperidone is useful. In very severe attacks, subcutaneous sumatriptan is first choice. The patient should be treated early in the attack, use an adequate dose and formulation of a medication. Ideally, acute therapy should be restricted to no more than 2 to 3 days per week to avoid medication overuse.

Entities:  

Keywords:  Migraine; acute; attack; treatment

Year:  2013        PMID: 28360580      PMCID: PMC5353074          DOI: 10.4274/Npa.y7299

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  44 in total

1.  Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double-blind, crossover, multicenter, phase III clinical trial.

Authors:  Vesile Öztürk; Mustafa Ertaş; Betül Baykan; Hadiye Sirin; Aynur Özge
Journal:  Pain Pract       Date:  2012-06-25       Impact factor: 3.183

2.  Prevalence and characteristics of migraine in women of reproductive age in Istanbul, Turkey: a population based survey.

Authors:  Ulkü Türk Börü; Abdulkadir Koçer; Arda Lüleci; Haydar Sur; Hava Tutkan; Hakki Atli
Journal:  Tohoku J Exp Med       Date:  2005-05       Impact factor: 1.848

3.  The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.

Authors:  H C Diener; V Pfaffenrath; L Pageler; H Peil; B Aicher
Journal:  Cephalalgia       Date:  2005-10       Impact factor: 6.292

4.  Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.

Authors: 
Journal:  Cephalalgia       Date:  1999-05       Impact factor: 6.292

5.  A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines.

Authors:  B W Friedman; J Corbo; R B Lipton; P E Bijur; D Esses; C Solorzano; E J Gallagher
Journal:  Neurology       Date:  2005-02-08       Impact factor: 9.910

6.  Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study.

Authors:  J Waelkens
Journal:  Cephalalgia       Date:  1984-06       Impact factor: 6.292

Review 7.  Prevalence of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andree
Journal:  J Headache Pain       Date:  2010-05-16       Impact factor: 7.277

8.  A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group.

Authors: 
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

9.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

Review 10.  Acute and preventive treatment of migraine.

Authors:  Paul B Rizzoli
Journal:  Continuum (Minneap Minn)       Date:  2012-08
View more
  2 in total

Review 1.  Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine.

Authors:  Sara Assadpour; Mohammad Reza Shiran; Peyman Asadi; Javad Akhtari; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2022-01-15       Impact factor: 3.411

2.  Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial.

Authors:  Licia Grazzi; Cristina Tassorelli; Marina de Tommaso; Giulia Pierangeli; Paolo Martelletti; Innocenzo Rainero; Pierangelo Geppetti; Anna Ambrosini; Paola Sarchielli; Eric Liebler; Piero Barbanti
Journal:  J Headache Pain       Date:  2018-10-19       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.